Financials
Financial year 2025
LA+PHARMA from Houthulst, company number BE0845973424, closed financial year 2025 with a result of € 127,041 after tax. For that financial year LA+PHARMA recorded a gross margin of € 359,945 and equity of € 614,605. Compared with financial year 2024, the result moved from € 124,491 to € 127,041. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 614,605
▲ 26% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 127,041
▲ 2% vs 2024
Profit after tax over the fiscal year.
€ 400,508
▲ 43% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 833 paid out
1 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
0.9
Average over the fiscal year, from the social balance sheet.
€ 71,179
▼ 2% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 24,782
▼ 22% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 408,645
▼ 8% vs 2024
€ 37,954 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 277,205
▲ 8% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 15,370
▼ 67% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 267,725 | € 348,893 | € 391,957 | € 359,945 | ▼ 8% |
| Profit after taxes | € 67,869 | € 122,400 | € 124,491 | € 127,041 | ▲ 2% |
| Equity | € 241,506 | € 363,907 | € 488,398 | € 614,605 | ▲ 26% |
| Total debts | € 880,522 | € 630,775 | € 865,760 | € 828,790 | ▼ 4% |
| Cash | € 308,721 | € 200,660 | € 280,663 | € 400,508 | ▲ 43% |
| Land & buildings | € 225,720 | € 210,672 | € 479,469 | € 461,021 | ▼ 4% |
| Retained profit | € 161,506 | € 283,907 | € 408,398 | € 534,605 | ▲ 31% |
| Dividend | € 0 | € 0 | € 0 | € 833 | |
| Bank debt | € 249,178 | € 215,603 | € 445,367 | € 408,645 | ▼ 8% |
| Balance sheet total | € 1,122,029 | € 994,682 | € 1,354,157 | € 1,443,395 | ▲ 7% |
| Employees (FTE) | 1 | 1 | 0.9 | 0.9 |
Key figures of LA+PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to LA+PHARMA?
What happened at LA+PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 127,041 (▲ 2% vs 2024). filed late Source: NBB ↗
- Gudrun Lafaut became a director. NBB
- New establishment in Houthulst. KBO
- Start of the company according to the CBE. KBO
In short
From € 67,869 profit in 2022 to € 127,041 profit in 2025.
Paid € 185,053 in corporate taxes since 2022.
Best year ever: 2025, with € 127,041 profit.
On average € 348,900 of value added per employee in 2023.
Management
Behind LA+PHARMA is Gudrun Lafaut.
Directors
According to the 2025 annual accounts
Gudrun Lafaut
Director
since 2019
Establishments
Establishment units
Physical locations of this company
Jonkershovestraat 276 B
8650 Houthulst
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Hosting
AMAZON-02 - Amazon.com, Inc., US
DNS
AWS Route 53
Website info
Features
Security
Network
Details
- Company number
- 0845.973.424
- VAT number
- BE 0845.973.424
- Registered office
- Jonkershovestraat 276 B, 8650 Houthulst
- Names & denominations
- LA+PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 May 2012
- Peppol
- Active · Active since 29 Sept 2025
- Contact
- apotheeklafaut.be
- Activities · NACE
Detailhandel in farmaceutische producten